SEC Form 4 · accession 0001140361-18-022045

Unity Biotechnology, Inc. · UBX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Executive Officer · Director

Period of report

May 7, 2018

Accepted (ET)

May 7, 2018 · 6:20 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001463361

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2	May 7, 2018	C	383,475	—	A	383,475	I	See Footnote
Common Stock^F1,F3	May 7, 2018	C	148,448	—	A	148,448	I	See Footnote
Common Stock^F1	May 7, 2018	C	1,630	—	A	150,782	D
Common Stock^F4	holding	—	—		—	152,542	I	See Footnote

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	D/I
Series B Preferred Stock^F1,F2,F5	—	May 7, 2018	C	383,475	D	—	—	Common Stock	383,475	I
Series B Preferred Stock^F1,F3,F5	—	May 7, 2018	C	148,448	D	—	—	Common Stock	148,448	I
Series C Preferred Stock^F1,F5	—	May 7, 2018	C	1,630	D	—	—	Common Stock	1,630	D

F1The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering.
F2The shares are directly held by Andalucia Ventures LLC, a limited liability company in which the Reporting Person holds a controlling interest.
F3The shares are directly held by Pathfinder Investment Fund, LLC, a limited liability company in which the Reporting Person holds a controlling interest.
F4The shares are directly held by Keith Richard Leonard, Jr. 2017 Retained Annuity Trust.
F5The expiration date is not relevant to the conversion of these securities.